IGF1R and lung adenocarcinoma: Wang et al. (2020) showed that, in the tumour microenvironment of lung adenocarcinoma, bone-marrow-derived MSCs produced molecules associated with adipocytes, which promoted resistance to the chemotherapeutic agent erlotinib in cancer cells by activating the insulin-like growth factor 1 receptor (IGF-1R).